# A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

> **NCT07435324** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **R-Pharm** · enrollment: 161 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** RPH-002
- **DRUG:** Erbitux®
- **DRUG:** Cisplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT07435324
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-08
- **Primary completion:** 2025-09-29
- **Final completion:** 2026-06-21
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07435324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07435324, "A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07435324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*